Vaccine candidate COVID-19 of the next generation of Moderna tested in participants of clinical trials

Vaccine candidate COVID-19 of the next generation of Moderna tested in participants of clinical trials

by

Moderna announced on Monday that it began administering its next-generation COVID-19 candidate vaccine in a Phase 1 study. The new candidate, mRNA-1283, can be stored in a refrigerator, which could ease the obstacles to storage and transportation.

“We are pleased to begin this Phase 1 study of our next generation COVID-19 candidate vaccine, mRNA-1283,” said Stephane Bancel, CEO of Moderna, in a press release on Monday. “Our investments in our mRNA platform have enabled us to develop this next generation candidate vaccine that is a potentially stable refrigerator vaccine that could facilitate distribution and administration in a wide range of configurations, potentially including for developing countries. We remain committed to helping address this continuing public health emergency.

The new clinical trial is evaluating three dose levels of mRNA-1283, which targets the peak protein SARS-CoV-2, given to healthy adults in a series of two doses with an interval of 28 days and at one level dose in a single injection.

The new clinical trial is evaluating three dose levels of mRNA-1283, which targets the spike protein SARS-CoV-2, administered to healthy adults in a series of two doses with an interval of 28 days and at a level of dose in a single shot.
(iStock)

The currently approved Modern two-dose vaccine can be stored refrigerated at 2 degrees Celsius to 8 degrees Celsius for up to 30 days before use, but cannot be refrozen after thawing. Unperforated vials can be stored between 8 degrees Celsius and 25 degrees Celsius for up to 12 hours, but they also cannot be frozen again.

‘PARTIAL’ PFIZER COVID-19 VACCINATION REDUCES THE RISK OF INFECTION BY 63% AMONG NURSING RESIDENTS: CDC

The new clinical trial is evaluating three dose levels of mRNA-1283, which targets the spike protein SARS-CoV-2, administered to healthy adults in a series of two doses with an interval of 28 days and at a level of dose in a single shot. The results will be compared with the dose level currently authorized in the two-dose series.

CLICK HERE FOR FULL CORONAVIRUS COVERAGE

“MRNA-1283 should be evaluated in future studies for use as a booster dose for previously vaccinated or seropositive individuals, as well as in a primary series for seronegative individuals,” the press release said.

Source